目的 研究全髋关节置换术对于股骨颈骨折老年患者的适用性。方法 回顾性分析本院2012年1月—2014年1月间收治的89例股骨颈骨折老年患者,根据不同治疗术式将患者分为两组,将其中采取人工全髋关节置换术治疗的56例患者纳入全髋组,以将其中采取半髋关节置换术治疗的33例患者纳入半髋组,对比两组患者的手术情况,随访一年评估疗效并统计功能恢复时间以及并发症发生情况。结果 半髋组各项手术情况观察指标均优于全髋组,P<0.05;治疗后随访一年,全髋组总有效为96.43%,半髋组总有效率为93.94%,全髋组疗效优于对照组,P<0.05;全髋组并发症发生率为3.57%,半髋组并发症发生率为18.18%,全髋组并发症发生率优于半髋组,P<0.01。结论 全髋关节置换术治疗股骨颈骨折老年患者适用性高于半髋关节置换术,可考虑作为老年患者的首选术式加以推广。

Objective To study the applicability of total hip arthroplasty in elderly patients with femoral neck fracture. Methods A retrospective analysis of 89 cases of elderly patients with femoral neck fracture in our hospital was made from January 2012 to January 2014, according to different surgical methods. The patients were divided into two groups, among them 56 cases of total hip arthroplasty were in the total hip group, and 33 cases of hip replacement were in the semi hip arthroplasty group. To compare the surgery condition, one year of follow-up evaluation of occurrence curative effect was made and added up the function recovery time and complications in the two groups. Results The surgical observation indicators in the semi arthroplasty group were better than the total hip group, P<0.05; follow-up one year after the treatment, the total effective rate of the total hip group was 96.43%, that in the semi hip arthroplasty group was 93.94%, thus the curative effect of the total hip group was better than the control group, P<0.05; The incidence of complications of the total hip arthroplasty group was 3.57%, that in the semi hip arthroplasty group was 18.18%, thus the incidence of complications of the total hip group was better than the semi hip group, P<0.01. Conclusion The adaptability of the total hip arthroplasty in the treatment of elderly patients with femoral neck fractures is better than the semi hip replacement surgery, and it may be considered as the first choice for the elderly patients to promote.

目的 研究雷公藤红素对人阿霉素耐药MCF-7/ADR乳腺癌细胞生长的作用。方法 采用MTT试验检测MCF-7/ADR细胞对阿霉素的耐药情况以及雷公藤红素对MCF-7/ADR细胞生长的影响;采用Annexin V-FITC/PI双染试验分析雷公藤红素对MCF-7/ADR耐药细胞凋亡的诱导作用;应用流式细胞周期分析检测雷公藤红素对MCF-7/ADR耐药细胞周期的影响。结果 MCF-7/ADR细胞对阿霉素耐药指数达14.54;而雷公藤红素能有效抑制阿霉素耐药细胞MCF-7/ADR的生长,并呈现浓度依赖性,作用48 h的IC50是1.04 μmol/L,MCF-7/ADR对雷公藤红素的耐药指数仅为0.87。2 μmol/L雷公藤红素作用8 h后,Annexin V-FITC染色阳性的MCF-7/ADR细胞比例较对照显著升高,差异有统计学意义(P＜0.05)。在1 μmol/L雷公藤红素作用24 h后,G1期细胞比例由对照(59.22±3.78)%升高至(77.44±4.21)%,而S期细胞比例由对照(37.51±2.91)%降至(19.65±2.25)%,差异有统计学意义(P＜0.05)。结论 雷公藤红素能激活MCF-7/ADR细胞凋亡的发生,并诱导MCF-7/ADR发生 G1/S细胞周期阻滞,从而对阿霉素耐药MCF-7/ADR细胞的生长发挥高效抑制作用。

Objective To investigate the effect of celastrol on the growth of adriamycin-resistant MCF-7/ADR breast cancer cells. Methods The resistance situation of MCF-7/ADR cells to adriamycin and the effect of celastrol on the growth of adriamycin-resistant MCF-7/ADR cells were evaluated by MTT assay. The effect of celastrol on apoptosis in MCF-7/ADR breast cancer cells was determined by annexin V-FITC/PI double staining. The effect of celastrol on cell cycle progression was determined by flow cytometry analysis. Results The resistance index of MCF-7/ADR cells to adriamycin was 14.54. After treatment with celastrol for 48 h, MCF-7/ADR cells displayed markedly inhibited growth in a dose-dependent manner, and calculated IC50 was 1.04 μmol/L. Celastrol decreased the resistance index of MCF-7/ADR from 14.54 to 0.87. The numbers of apoptotic MCF-7/ADR cells, as revealed by annexin V binding, significantly increased upon celastrol treatment (P＜0.05). Celastrol treatment caused an increase of cells in G1 phase from (59.22±3.78)% to (77.44±4.21)%, while the percentage of cells in S phase was decreased from(37.51±2.91)% to(19.65±2.25)%(P＜0.05). Conclusion These data demonstrated that celastrol induced apoptosis and G1/S cell cycle arrest in MCF-7/ADR cells and consequently displayed potent cytocidal effect on adriamycin-resistant MCF-7/ADR breast cancer cells.

目的 观察紫河车提取物联合顺铂对人脑胶质瘤细胞增殖与凋亡的影响。方法 把正常培养传代后的U251胶质瘤细胞按随机分配的方法分为四组,A组仅加普通培养液,B、C、D组各加紫河车提取物(400 mg/mL)2 mL、顺铂(1 mg/mL)0.01 mL、紫河车提取物(400 mg/mL)2 mL＋顺铂(1 mg/mL)0.01 mL;MTT法观察U251细胞增殖情况,流式细胞仪检测U251细胞凋亡率。结果 培养12、24、36、48、60 h,B、C、D组细胞增殖指数逐渐下降,与A组进行比较,各组P值均小于0.05;其中,将D组与B、C组进行比较,P值小于0.05。将各组培养24 h后上机,测得A、B、C、D各组细胞的凋亡率分别为(0.3±0.2)%,(10.6±1.5)%,(35.9±2.8)%,(52.1±4.1)%。其中,B、C、D各组和A组进行比较,P值均小于0.05;将D组与B、C组两组进行比较,P值也均小于0.05。结论 紫河车提取物联合顺铂可抑制人脑胶质瘤U251细胞增殖,并诱导其凋亡。

Objective To observe the effect of cisplatin combinated with the placental immunoregulating polypeptide (PIP) on proliferation and apoptosis of glioma cells. Methods Randomly we divide the normal handed U251 glioma cells into four groups. We added ordinary nutrient solution to group A, while added activated PIP(400 mg/mL)2 mL to group B, cisplatin (1 mg/ml) 0.01 ml to group C, PIP 400 mg/mL)2 mL and cisplatin (1 mg/mL) 0.01 mL to group D. We surveyed the proliferation rate of gliobma cells by MTT experimental method and analyzed the apoptosis of U251 glioma cells by flow cytometry. Results The index of cell proliferation of group B,C,D declined gradually with the training of 12 h,24 h,36 h,48 h,60 h. Compared B, C,D group with A group, P<0.05,and compared group D with group B and group C, P< 0.05. Put groups culturing of 24 hour on flow cytometer, the glioma cells apoptosis rate of each group was 0.3%±0.2%、10.6%±1.5%、35.9%±2.8%、52.1%±4.1% respectively. Compared group B,C,D with group A, P<0.05,and compared group D with group B and group C, P<0.05. Conclusion Placental immunoregulatingpPolypeptide combined with cisplatin may restrain the proliferation of human glioma cells, meanwhile increase the apoptosis of glioma cells.

目的 观察乳腺癌组织中沉默信息调节因子(SIRT1)的表达并探讨其临床意义。方法 选取70例乳腺癌组织和20例乳腺纤维腺瘤组织,应用免疫组化法观察SIRI1在两组中的表达,并分析其与临床病理参数、预后之间的关系。结果 SIRT1在乳腺癌组织中和乳腺纤维腺瘤组织中的阳性表达分别为:62.9%(44/70)、35%(7/20),P＜0.05;SIRT1的表达与乳腺癌的病理分期及淋巴结转移有关,P＜0.05;SIRT1表达阳性和阴性患者2年无疾病进展生存率分别为40.6%和73.7%,P＜0.05。结论 乳腺癌组织中SIRT1的阳性表达率较高,并与乳腺癌的发生、发展、侵袭、转移、预后有关。

Objective To investigate the sirtuin (SIRT1) expression in breast cancer and its relationship with clinicopathological parameters in breast tissue. Methods We used immunohistochemical staining (Envision two-step) to detect the expression of 70 cases of breast cancer and 20 cases of breast fibroadenoma of SIRT1. Results The positive expression of sirt1 in breast cancer and breast fibroadenoma tissues were 62.9 % (44/70) and 35 % (7/20),P<0.05. The expression of sirt1 was correlated with the pathological stage and lymph node metastasis of breast cancer, P<0.05. The 2-year survival rates of sirt1 positive and negative patients were 40.6 % and 73.7 %, respectively, P<0.05. Conclusion The positive expression rate of sirt1 in breast cancer is higher, and is related to the occurrence, development, invasion, metastasis and prognosis of breast cancer.

目的 探讨结肠系膜局限型Castleman病的临床病理特征。方法 回顾性分析发生在结肠系膜的Castleman病1例,并结合相关文献及免疫组织化学技术进行分析。结果 诊断Castleman病(透明血管型),系原发于乙状结肠肠系膜内。结论 原发于乙状结肠肠系膜局灶型Castleman病,较为罕见,施行肿块手术切除,预后好,随访2年10个月无复发。

Objective To investigate the clinical and pathological features of mesocolon localized Castleman's disease. Methods A retrospective analysis of 1 case of localized Castleman's disease, occurred in the mesocolon, and unifies the immunohistochemical technique and pertinent literature. Results The Castleman disease (hyaline vascular type) isdiagnosed primary sigmoid mesentery. Conclusion Primary sigmoid mesentery localized Castleman's disease is a rare tumor. After surgical resection, prognosis is good, followed up for 10 months without recurrence.

通过文献检索,对2001—2016年我国学者在国内发表的有关人工髋关节置换后假体周围骨折的Vancouver分型及其治疗方法进行汇总、归纳和分析, 总结分析国内初次生物型人工髋关节术后假体周围骨折病例的Vancouver分型及其不同治疗方法的优良率,为临床决策中选择适合的手术方法提供一定的参考借鉴。共有 117 篇文献入选,统计结果显示入选病例数前三位的省份分别是河南220例占13.3%,上海173例占10.5%,江苏163例占9.9%;Vancouver分型中A型骨折201例占12.2%,B型骨折1226例占74.4%,C型骨折221例占13.4%。AG型骨折行记忆合金环抱器或钢丝环扎+植骨治疗,AL型骨折行翻修+锁定钢板+钢丝或翻修+锁定钢板+植骨治疗,疗效显著;B1、B2、B3型骨折分别采用加压钢板+植骨、翻修+钢板+钢丝+植骨、翻修+记忆合金环抱器+植骨治疗,术后平均优良率可达100%;C 型骨折治疗方法较多,如LISS钢板+植骨、锁定钢板+钢丝、股骨髁钢板+钢缆+植骨、动力髋钢板+钢丝,疗效均较满意。我国人工髋关节置换术地区间开展不平衡,应根据Vancouver 分型,综合考虑患者骨折类型、骨折位置、假体稳定性、骨量丢失情况等提出个体化的治疗方案,提高临床疗效。

目的 探究一次性带冲洗球囊胃管的临床应用。方法 收集来我院进行腹部外科手术的患者共200例,随机分为研究组与对照组,每组100例,其中研究组患者采用一次性带球囊胃管治疗,对照组则应用传统胃管进行治疗。观察对比2组患者进行引流的通畅情况、治愈时间、胃管滑脱及胃管相关并发症等情况。结果 研究组患者的一次置管成功率高于对照组(P＜0.05),置管停顿率和自行拔管率均低于对照组(P＜0.05);研究组低于对照组(P＜0.05);研究组患者的不良反应发生率低于对照组(P＜0.05),差异均有统计学意义。结论 一次性带冲洗球囊胃管治疗可持续冲洗胃腔及灌注药物,保证引流通畅,明显提高胃肠减压效果,促进胃黏膜的炎症水肿、糜烂出血等病症的修复愈合,并且能够提高置管效果,减少置管时间,同时避免不良反应的发生,值得临床进一步推广。

Objective To investigate the clinical value of disposable balloon catheter with irrigation. Methods In our hospital for abdominal surgery patients with a total of 200 cases were randomly divided into study group and control group, 100 cases in each group. The study group was treated by disposable balloon intubation, the control group used conventional gastric tube. Observation and comparison of two groups were taken with drainage patency, cure time, gastric tube slippage and gastric tube related complications. Results The study group of patients with a success rate of catheterization was higher than that of the control group (P<0.05), catheter pause rate and self extubation rate were lower than that of the control group (P<0.05); the study group was significantly lower than that of the control group (P<0.05); the adverse reaction of patients in the study group was significantly lower than that of the control group (P<0.05), the differences were statistically significant. Conclusion Disposable flushing balloon intubation treatment of gastric cavity perfusion and sustainable irrigation, to ensure smooth drainage, may improve the effect of gastrointestinal decompression, promote the repair of gastric mucosal inflammation and edema, erosion, bleeding and other symptoms and improve the effect of catheterization, reduce the intubation time, and avoid the occurrence of adverse reactions. It is worthy of further promotion.

目的 观察比较术中及术前化疗干预对进展期胃恶性肿瘤手术患者p53、ki-67表达及预后的影响,为临床化疗时间的选择提供理论依据。方法 自2014年8月—2015年5月,我院共收入胃恶性肿瘤患者40例,将40例患者随机分为两组,每组各20例,保证两组患者在性别、年龄、胃癌分期等方面可比,无统计学差异(P＞0.05),标记为Ⅰ组和Ⅱ组。Ⅰ组20例患者于术前进行化疗干预,Ⅱ组在术中给予化疗干预。观察比较两组患者p53、ki-67表达状况及预后。结果 Ⅰ组及Ⅱ组治疗后p53及ki-67均比治疗前升高,差异有统计学意义(P<0.05)。但是治疗后,Ⅰ组和Ⅱ组的p53表达状况组间差异不明显,无统计学意义(P>0.05)。治疗前后,AI差异有统计学意义(P<0.05)。Ⅰ组效果明显好于Ⅱ组,两者差异有统计学意义(P <0.05)。术后六个月、一年随访时发现两组复发率、死亡率差别不大,无统计学意义(P>0.05),术后两年随访发现Ⅱ组复发率、死亡率明显低于Ⅰ组,差异有统计学意义(P<0.05)。结论 术中化疗的疗效优于术前化疗,患者预后较术前化疗好。

Objective To observe the effect of intraoperative and preoperative chemotherapy on the expression of p53, Ki-67 and prognosis in patients with advanced gastric cancer. Methods 40 cases of advanced gastric cancer in our hospital from Aug 2014 to May 2015 were enrolled in the study, and were divide into 2 groups randomly. In group I, 20 patients received chemotherapy intervention befoerer operation, and the other group received chemotherapy intervention during operation. The expressions and prognosis of p53 and Ki-67 were observed and compared between the two groups. Results Group Ⅰ and group Ⅱ after treatment, p53 and Ki-67 were higher than that before treatment, with statistical significance(P<0.05). However, there was no significant difference in the expression of p53 between group Ⅰ and group Ⅱ after treatment, and there was no significant difference(P>0.05). Before and after treatment, the difference of AI was significant, with statistical significance (P<0.05). The effect of group Ⅰ was obviously better than that of group Ⅱ, the difference was statistically significant(P<0.05). Six monthse after the operation and one year follow-up found two groups of recurrence rate and mortality rate had no significant difference(P>0.05). After two years follow-up found the group Ⅱ recurrence rate, mortality was lower than in group Ⅰ (P<0.05). Conclusion The effect of intraoperative chemotherapy is better than that of preoperative chemotherapy, and the prognosis is better than that of preoperative chemotherapy.

目的 探讨乳腺深部脓肿患者采用麦默通微创旋切术治疗与传统切开引流术比较。方法 选取2016年2月—2017年1月我院收治乳腺深部脓肿患者62例为研究对象,根据患者自愿选择手术方式分为麦默通组(麦默通微创旋切术,38例)和传统组(传统切开引流术,24例),比较两组患者手术时间、术中出血量、住院时间、术后1 d疼痛、手术切口长度,并对两组患者随访6个月,比较脓肿复发及切口感染、乳房变形、皮肤感觉障碍、乳瘘等并发症发生率。结果 麦默通组患者手术时间、术中出血量、住院时间、术后1 d疼痛、手术切口长度均少于传统组(P＜0.05)。两组患者术后脓肿复发率无统计学意义(P＞0.05);麦默通组患者术后切口感染、乳房变性、皮肤感觉障碍、乳瘘发生率均低于传统组(P＞0.05)。结论 乳腺深部脓肿患者采用麦默通微创旋切术治疗,相对传统切口引流术可减轻患者手术创伤、缩短患者术后康复时间,降低术后并发症发生率,具有更为显著临床疗效。

目的 研究孟鲁斯特治疗哮喘的临床疗效及其对患者Th1/Th2细胞免疫平衡和相关炎症因子水平的影响。方法 选取哮喘患者68例随机分为对照组31例及观察组37例,对照组予以常规糖皮质激素吸入治疗,观察组在此基础上加服孟鲁斯特。用药3个月后流式细胞仪检测两组患者外周血Th1、Th2数量变化,ELISA定量外周血IL-4及IFN-γ含量变化并作临床效果评定。结果 两组患者经治疗后,外周血Th1/Th2比例均升高,IL-4/IFN-γ细胞因子水平下降,但观察组较对照组变化更为明显,差异有统计学意义(P＜0.01)。疗效方面,观察组总有效率94.59%,高于对照组的74.19%,差异具有统计学意义(P＜0.01),同时两组均未见明显不良反应。结论 哮喘患者加用孟鲁斯特具有明显免疫调节功能,使Th1/Th2水平趋于平衡,作为哮喘辅助治疗药物疗效确切。